The Toronto-listed biotech's stock has fallen hard since 2024. Whether it recovers comes down to a handful of concrete trial readouts and a persistent cash constraint.

Medicenna Therapeutics (TSX: MDNA) has spent 2026 trading nowhere near where it sat in 2024, but the company's underlying pipeline has kept moving. Whether the stock re-rates meaningfully over the next year and a half comes down to a small number of concrete events — and one real constraint: cash.

The trial readout everyone's waiting on

The company's lead asset, MDNA11 — a modified IL-2 "super agonist" — has been running through the Phase 1/2 ABILITY-1 study, testing it in patients with solid tumors who've stopped responding to standard checkpoint inhibitors. Enrollment wrapped in the third quarter of 2026, with updated data expected in the fourth quarter. Earlier readouts showed response rates in the 30 to 40 percent range in that hard-to-treat population, including a 42 percent objective response rate among patients given MDNA11 as their very next treatment after a checkpoint inhibitor failed — a meaningful number in oncology, where most late-line therapies struggle to clear 15 to 20 percent.

The Q4 data matters because it's what Medicenna says will determine its regulatory path — specifically, whether it can get FDA guidance on a registrational trial design before year-end. That's the single biggest near-term catalyst for the stock.

Two more programs in the background

Bizaxofusp, aimed at recurrent glioblastoma, is already Phase 3-ready and holds FDA Fast Track and Orphan Drug status — but Medicenna isn't funding that trial alone. It's pursuing a partner to take it forward, and a signed deal would be a distinct catalyst separate from anything MDNA11 does. Behind that sits MDNA113, an earlier-stage bispecific drug still in preclinical testing, with an IND filing targeted for the fourth quarter of 2026 and a first human trial planned for 2027.

The constraint that caps all of it

None of this changes the fact that Medicenna is a small, pre-revenue biotech that loses money every quarter — its net loss widened to roughly C$18.4 million for the fiscal year ended March 2026, up from C$11.8 million the year before. Cash on hand has been in the single-digit millions, and the company has said financing activity should extend its runway into 2027 — but that runway depends on continuing to raise money, which it's done through smaller offerings and financing arrangements throughout the year rather than one large raise.

That's the honest shape of the situation: a real, data-backed drug candidate with a genuine near-term catalyst in Q4 2026, sitting inside a company that will likely need to raise capital again before any of that data translates into commercial value — standard for clinical-stage biotech, but real dilution risk for existing shareholders all the same.